🇺🇸 FDA
Pipeline program

INFLIXIMAB, DS-8201a, AZD6738, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion.

D6185C00001

Phase 3 small_molecule active

Quick answer

INFLIXIMAB, DS-8201a, AZD6738, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion. for Patients with non-small cell lung cancer (NSCLC). is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Patients with non-small cell lung cancer (NSCLC).
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials